

# The PREVENT Project

<https://www.neurodegenerationresearch.eu/survey/the-prevent-project/>

## **Principal Investigators**

Professor Craig Ritchie

## **Institution**

Imperial College London

## **Contact information of lead PI**

### **Country**

United Kingdom

## **Title of project or programme**

The PREVENT Project

## **Source of funding information**

Alzheimer's Society

## **Total sum awarded (Euro)**

€ 537,674

## **Start date of award**

01/08/2016

## **Total duration of award in years**

3.0

## **The project/programme is most relevant to:**

Alzheimer's disease & other dementias

## **Keywords**

Neurodegenerative disease in general

## **Research Abstract**

The PREVENT Pilot study has been successfully running in Imperial College since February 2014. To date we have recruited 201 participants to the study with the protocol proving to be both feasible and acceptable to participants. The aim of this application is to expand recruitment in 3 sites (Imperial, Oxford and Cambridge) to ensure that 350 participants are recruited. A separate application from Edinburgh to local philanthropists will cover national tasks for the

project and recruitment in Scotland of a further 300 subjects. It was always envisaged that post-pilot phase expansion would be needed. The PREVENT project will become the largest mid-life cohort purposed for neurodegenerative disease in the world. It will make a major contribution to the science of disease modelling in early disease, it will continue to enable other research efforts and will be able to make a greater contribution to scientists in the Dementia Platform UK (of which it is a foundation cohorts). Moreover, as a Parent Cohort in the IMI-funded EPAD (European Prevention of Alzheimer's Dementia) Consortium, extended recruitment will ensure that more people will be able to transition into the EPAD cohort and thereafter EPAD trial. The PREVENT project is uniquely placed to provide the highest quality data across a range of putative risks as well as cognitive and biomarkers of neurodegenerative disease. The pilot phase was very succesful so to ensure even more powerful modelling and greater enablement of other projects, we seek to extend recruitment to a sample of over 600 nationally.

### **Lay Summary**

**Further information available at:**

#### **Types:**

Investments > €500k

#### **Member States:**

United Kingdom

#### **Diseases:**

Alzheimer's disease & other dementias

#### **Years:**

2016

#### **Database Categories:**

N/A

#### **Database Tags:**

N/A